Drug Sales Trends for VICODIN ES

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for VICODIN ES

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
VICODIN ES			2022
VICODIN ES			2021
VICODIN ES			2020

VICODIN ES Market Analysis and Sales Projections

Last updated: February 27, 2026

VICODIN ES, a combination hydrocodone and acetaminophen product, is marketed for pain management. The drug’s market position is influenced by regulatory, competitive, and prescriptive factors.

Market Overview

VICODIN ES primarily serves acute and chronic pain markets in the U.S. It faces competition from similar opioid formulations and non-opioid analgesics. The product’s growth potential depends on regulatory changes, prescribing trends, and the opioid epidemic response.

Regulatory Environment

• The Drug Enforcement Administration (DEA) classified hydrocodone combination products as Schedule II drugs in 2014.
• In 2020, the FDA issued new labeling requirements for opioid medications, including entities like VICODIN ES, to limit misuse.
• The CDC’s 2016 guidelines discourage long-term opioid use for chronic pain, impacting sales volumes.

Market Size

• The U.S. opioid analgesics market was valued at approximately USD 5 billion in 2022.
• Hydrocodone-based products account for about 60% of opioid prescriptions, approximating USD 3 billion annually.
• VICODIN ES holds an estimated 10-15% market share among formulary-listed hydrocodone products.

Competitive Landscape

Main competitors include:

Product Name	Market Share	Formulation Type	Price Point	Key Differentiator
Norco	40%	Hydrocodone + acetaminophen	Moderate	Established brand presence
Lortab	20%	Hydrocodone + acetaminophen	Lower	Generic availability
Zohydro ER	10%	Hydrocodone ER	Higher	Extended-release formulation

The generic hydrocodone-acetaminophen remains the dominant market force, constraining branded sales.

Sales Projections (2023-2027)

Assumptions:

• A compound annual growth rate (CAGR) of 2-3%, driven by new prescribing practices and evolving regulations.
• Market share remains stable at approximately 10% within the hydrocodone segment.
• Overall opioid prescriptions decline by 5% annually due to increased regulation and alternative pain management.

Estimated Sales (USD in millions):

Year	Total U.S. Opioid Market	VICODIN ES Sales Projection	Comments
2023	4.75 billion	45	Slight decline due to regulatory pressures
2024	4.51 billion	43	Market contraction continues
2025	4.28 billion	41	Prescriber shift towards non-opioid options
2026	4.06 billion	39	Saturation of existing market segments
2027	3.86 billion	37	Further decline expected

Revenue Drivers:

• Incremental increases may result from expanded indications or formulations.
• Market share may increase with targeted marketing or patent protections.

Key Risks

• Growing regulatory scrutiny threatens sales volume.
• Increased use of abuse-deterrent formulations reduces demand.
• Competition from non-opioid analgesics gains traction.
• Legal actions related to opioid litigation can restrict sales.

Market Entry and Expansion Strategies

1. Formulation innovation focusing on abuse deterrence.
2. Strategic partnerships with healthcare providers.
3. Diversification into extended-release variants.
4. Enhanced educational campaigns on responsible prescribing.
5. Monitoring legislative developments to adapt swiftly.

Key Takeaways

• VICODIN ES’s market relies heavily on the opioid prescribing environment, which is under increasing regulation.
• Market share remains constrained by competition from generics and alternative therapies.
• Sales are projected to decline modestly over the next five years, aligned with industry trends.
• Growth opportunities exist through product innovation, though regulatory and legal challenges persist.

FAQs

1. What factors most influence VICODIN ES sales?
   Prescribing trends, regulatory policies, healthcare provider preferences, and competition from generics shape sales dynamics.

2. How does regulatory pressure affect oxycodone-based products?
   Increased restrictions and demand reduction efforts lower prescription volumes and sales.

3. Are extended-release formulations more profitable?
   They often command higher prices and have longer market longevity but face strict approval and competition challenges.

4. What role do legal risks play in market outlooks?
   Litigation concerns may impact manufacturing, marketing, and sales strategies significantly.

5. Can non-opioid pain medications replace VICODIN ES?
   Increased use of non-opioid options reduces reliance on opioids, impacting future sales growth.

---

Sources

1. U.S. Food and Drug Administration. (2020). FDA Updates Labeling for Opioid Medications.
2. Centers for Disease Control and Prevention. (2016). Guidelines for Prescribing Opioids for Chronic Pain.
3. Grand View Research. (2022). Opioid Market Size, Share & Trends.
4. IQVIA. (2022). U.S. Prescription Drug Market Data.
5. U.S. DEA. (2014). Rescheduling of Hydrocodone Combinations.